|
| |
|
|
|
More Tools and information | | Search for suppliers of |  Trade Associations |
|
Newsletters |
Your Gateway to a Fast
Changing World
Product News Alerts |
 |
Receive similar stories and other customized
news to keep you in the know on the products shaping
industry. |
Subscribe Free Today
Subscribe View
Sample |
Industrial
Market Trends
Has Got It |
- Latest developments
- Trends
- Best practices
- Opinions & Commentary
|
 |
Get Ahead.
Get IMT.
Subscribe Free Today
Subscribe View
Sample |
|
|
|
AARP Drug Price Survey Overlooks Critical Factors, Says BIO Biotechnology Industry Organization Release date: September 26, 2008
Report Ignores Impact of Discounts, Rebates, Negotiated Prices and Patient Assistance Programs That Help Lower Drug Costs
Contact Jeff Joseph
(202) 962-9230
WASHINGTON, D.C. (September 26, 2008) - The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding a new survey from the AARP on price trends for biotechnology drugs:
"The report issued yesterday by the AARP on price trends for specialty drugs ignores the many factors that counter and mitigate the price trends mentioned in this analysis. The report focuses on data that is only a proxy for drug pricing in Medicare's Part D program.
"The AARP survey centers on a subset of drugs available to Medicare beneficiaries and does not take into account the discounts, rebates and other negotiated prices that evidence suggests are passed on to Medicare beneficiaries in the form of lower premiums, copayments and deductibles in the Medicare Part D program, resulting in a decrease in the overall cost of that program. These discounts, as a result of vigorous negotiation between manufacturers and Part D plans, have resulted in lower costs throughout the Part D benefit. Kerry Weems, Acting Administrator of the Centers for Medicare & Medicaid Services (CMS), recently noted that the average monthly premiums for stand-alone drug plans in 2009 are lower than originally estimated and that it is a competitive market. He added that 97% of beneficiaries in 2009 will have access to drug coverage for the same amount or less than they paid this year.
"In addition, studies show that approximately one-third of Medicare Part D beneficiaries receive some form of assistance or subsidy that helps lower copayments, deductibles and premiums for their specialty drugs.
"The AARP survey is based on the wholesale acquisition cost (WAC) of these drugs, which does not reflect negotiated discounts and rebates between manufacturers and Part D plan sponsors, nor is it the price used by the federal government for the reimbursement of the majority of drugs and biologics used by Medicare beneficiaries in Medicare Parts B and D. The plans that contract with the government have the discretion to pass rebates through to beneficiaries at the point of sale, and plans may wish to consider doing so for specialty products. The majority of manufacturers - particularly those with specialty products - provide funding for programs that assist patients with accessing needed therapies.
"Biotechnology medicines and therapies are achieving major advances against some of the most debilitating diseases facing the world today such as cancer, multiple sclerosis and orphan diseases. Biotechnology innovators share a goal of increasing access to these life-saving and life-enhancing drugs. We look forward to participating in public health discussions that help us move toward this goal."
Upcoming BIO Events
Intellectual Property Council Committee Fall Conference and Meeting
October 20-22, 2008
Orlando, Fla.
BIO HR Conference 2008
October 26-28, 2008
San Diego, Calif.
BIO-LES Advanced Business Development Course
October 27-29, 2008
San Francisco, Calif.
BIO Investor Forum 2008
October 29-31, 2008
San Francisco, Calif.
Advanced Business Development Course
November 14-16, 2008
Mannheim/Heidelberg, Germany
BIO-Europe 2008
November 17-19, 2008
Mannheim/Heidelberg, Germany
2009 BIO International Convention
May 18-21, 2009
Atlanta, Ga.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. www.bio.org
Contacts:
General Information:
Jeff Joseph
USA
Phone: 202-962-9230
Company Information:
Name: Biotechnology Industry Organization
Address: 1201 Maryland Ave., SW, Ste. 900
City: Washington
State: DC
ZIP: 20024
Country: USA
Phone: 202-962-9200
http://bio.org
|
Other News from this company: |
|
|
U.S. Farmers Prefer Biotech Varieties of Corn, Cotton, Soybeans
|
|
|
BIO Comments on White House Letter on Biosimilars
|
|
|
BIO Comments On Medicare Drug Discount Agreement Announced by PhRMA, the White House and Senate Finance Committee
|
|
|
BIO Commends Selection of Kappos to Lead PTO
|
|
|
BIO Commends Senate Committee on Small Business and Entrepreneurship's SBIR Reauthorization
|
|
|
FTC Report on Biosimilars Is Fundamentally Flawed
|
|
|
AARP Biologics Study Based on Fuzzy Math, Flawed Assumptions
|
|
|
BIO Asks EPA To Maintain Flexibility in Life Cycle Analysis for Renewable Fuel Standard
|
|
|
Bio Lauds New NIH Grants Offering Portion of Stimulus Funds to Small R&D Companies
|
|
|
Industry Leaders, Executives to Highlight Biobased Plastics and Chemicals at World Congress on Industrial Biotechnology
|
|
|
2009 BIO International Convention Attracted Global Industry Leaders and Public Officials for Networking, Deal Making and Partnering
|
|
|
Sustainable Farming Provided by Biotech Crops
|
|
|
Jay Keasling Receives Inaugural Biotech Humanitarian Award
|
|
|
Bioscience Education Study Finds Some States Lagging
|
|
|
2009 BIO International Convention to Host US Governors, International Public Officials
|
|
|
BIO Is Confident That Biofuels Can Meet Goals of Renewable Fuel Standard
|
|
|
BIO Elects New Officers, Welcomes 10 New Board Members
|
|
|
Scientific American Worldview Surveys Bio-Innovation Across the Globe
|
|
|
BIO Heads Back to Chicago
|
|
|
The Honourable Dalton McGuinty, Premier of Ontario, Canada, to Receive BIO International Leader Award
|
|
del.icio.us
DIGG
Facebook
Reddit
StumbleUpon
Twitter
![[Get Copyright Permissions]](http://license.icopyright.net/images/icopy-w.gif){kind=small}
